Australija - anglų - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; sodium carbonate; hyprolose; iron oxide yellow; calcium stearate; crospovidone; hypromellose; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1) - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion:- i) duodenal ulcer, ii) gastric ulcer, iii) gastro-oesophageal reflux disease (gord): symptomatic gord. the treatment of heartburn and other symptoms associated with gord; reflux oesophagitis iv) gastrointestinal lesions refractory h2 blockers v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics; i) clarithromycin and amoxicillin, or ii) clarithromycin and metronidazole, or iii) amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism. 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

proficient rx lp - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets, usp and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets, usp are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium extended-release tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions , and precautions, general: preexisting asthma ). diclofenac sodium extended-release tablets are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (cabg

Tanzanija - anglų - Tanzania Medicinces & Medical Devices Authority

abacus pharma africa limited, tanzania - diclofenac - tablets - 50mg

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

archis pharma llc - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). diclofenac potassium tablets are indicated: •for treatment of primary dysmenorrhea •for relief of mild to moderate pain •for relief of the signs and symptoms of osteoarthritis •for relief of the signs and symptoms of rheumatoid arthritis diclofenac potassium tablets are contraindicated in the following patients: •known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings: anaphylactic reactions, serious skin reactions). •history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been repo

Kanada - anglų - Health Canada

pharmascience inc - diclofenac sodium - tablet (enteric-coated) - 25mg - diclofenac sodium 25mg - other nonsteroidal antiimflammatory agents

Kanada - anglų - Health Canada

pharmascience inc - diclofenac sodium - tablet (enteric-coated) - 50mg - diclofenac sodium 50mg - other nonsteroidal antiimflammatory agents

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

apotex nz ltd - diclofenac sodium 25mg - enteric coated tablet - 25 mg - active: diclofenac sodium 25mg excipient: dextrates hydrated silica hypromellose iron oxide yellow   macrogol 3350 magnesium stearate methanol methylcellulose polyvinyl acetate purified water quinoline yellow stearic acid   sunset yellow aluminium lake     titanium dioxide   triethyl citrate - diclofenac is used for the relief of moderate pain and inflammation in: 1. rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. 2. acute attacks of gout. 3. painful post-operative inflammation and swelling (including dental and orthopaedic procedures). 4. painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. 5. as an adjuvant in severe painful inflammatory infections of the ear, nose or throat. 6. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

apotex nz ltd - diclofenac sodium 25mg - enteric coated tablet - 25 mg - active: diclofenac sodium 25mg excipient: dextrates hydrated silica hypromellose iron oxide yellow   macrogol 3350 magnesium stearate methanol methylcellulose polyvinyl acetate purified water stearic acid   sunset yellow aluminium lake       titanium dioxide   triethyl citrate - diclofenac is used for the relief of moderate pain and inflammation in: 1. rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. 2. acute attacks of gout. 3. painful post-operative inflammation and swelling (including dental and orthopaedic procedures). 4. painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. 5. as an adjuvant in severe painful inflammatory infections of the ear, nose or throat. 6. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

apotex nz ltd - diclofenac sodium 50mg - enteric coated tablet - 50 mg - active: diclofenac sodium 50mg excipient: colloidal silicon dioxide dextrates hypromellose iron oxide yellow   macrogol 3350 magnesium stearate methanol methylcellulose polyvinylacetate phthalate purified water stearic acid   sunset yellow aluminium lake   titanium dioxide   triethyl citrate - diclofenac is used for the relief of moderate pain and inflammation in: 1. rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. 2. acute attacks of gout. 3. painful post-operative inflammation and swelling (including dental and orthopaedic procedures). 4. painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. 5. as an adjuvant in severe painful inflammatory infections of the ear, nose or throat. 6. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

sandoz inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets, usp and other treatment options before deciding to use diclofenac sodium extended-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium extended-release tablets, usp are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac sodium extended-release tablets, usp is contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium extended-release tablets, usp should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactic reactions, and precautions, preexisting asthma). diclofenac sodium extended-release